Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391025 · ClinicalTrials.gov registry record · Early Phase 1
Gallium-68 Citrate PET Used in Prostate Cancer
A Early Phase 1 study of Prostatic Neoplasms, sponsored by Rahul Aggarwal.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02391025: Completed Early Phase 1 study of Prostatic Neoplasms, sponsored by Rahul Aggarwal.
NCT02391025 is a Early Phase 1 study of Prostatic Neoplasms that has completed, run by Rahul Aggarwal. The registered enrollment target is 39 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02391025, a Early Phase 1 study of Prostatic Neoplasms, has completed, sponsored by Rahul Aggarwal.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of participants with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition.
Primary Outcome
The mean and standard deviation of SUVmax of gallium-68 citrate (across all metastatic lesions per participant) will be reported.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium-68 citrate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-05-28 |
| Est. Completion | 2023-06-15 |
| Phase | Early Phase 1 |
What the finished NCT02391025 record still lists
NCT02391025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT02391025 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02391025 about?
NCT02391025 is a clinical study titled "Gallium-68 Citrate PET Used in Prostate Cancer". This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will con...
What is the current status of trial NCT02391025?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2015-05-28. Estimated completion is 2023-06-15.
What conditions does trial NCT02391025 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02391025?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Gallium-68 citrate (DRUG).
Who is sponsoring clinical trial NCT02391025?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02391025 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02391025's enrollment target sits among peer trials
39 51st of 65 higher than 15 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-DCFBC PET/CT in Prostate Cancer
COMPLETED · Early Phase 1
-
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
COMPLETED · Early Phase 1
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI